tbuckley/cabot-search huggingface dataset:
The epidemiology of professional ice hockey injuries: a prospective report of six NHL seasons
Authors: Carly D McKay, Raymond J Tufts, Benjamin Shaffer, Willem H Meeuwisse
Journal: British Journal of Sports Medicine (2013)

There is a paucity of literature examining injury and illness rates in men's professional ice hockey. This study aimed to determine injury and illness rates in the NHL over six seasons, and identify predictors of injury-related time loss in this population.This study involved an inclusive cohort of hockey players from all NHL teams competing in the 2006-2007 through 2011-2012 seasons. A standardised electronic injury surveillance system was used to report injury and illness events. The primary outcome was regular season and postseason time-loss injury/illness. The secondary outcome was man-games lost from the competition.On the basis of the estimated athlete exposures (AEs), the overall regular season incidence density was 15.6 injuries/1000 AEs and 0.7 illnesses/1000 AEs. Based on recorded time on ice, the injury rates were roughly threefold higher at 49.4 injuries/1000 player game-hours and 2.4 illnesses/1000 player game-hours. There was a reduction in injury rates over the 6-year period, with the greatest reduction between the 2007-2008 and 2008-2009 seasons. Multivariate predictors of time loss greater than 10 days were being a goalie (OR=1.68, 95% CI 1.18 to 2.38), being injured in a road game (OR=1.43, 95% CI 1.25 to 1.63) and the mechanism of injury being a body check (OR=2.21, 95% CI 1.86 to 2.62).There was an overall reduction in the time-loss injury and illness rates over six seasons. Being a goaltender, being injured on the road and being injured by a body check were the risk factors for time loss greater than five 'man games'.
Breast Cancer Prognosis
Authors: Joan Stephenson
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Environmental factors modulate the effect of the APOE genetic polymorphism on plasma lipid concentrations: Ecogenetic studies in a Mediterranean Spanish population
Authors: Dolores Corella, Marisa Guill[eacute]n, Carmen S[aacute]iz, Olga Portol[eacute]s, Antonio Sabater, Silvia Cortina, Jos[eacute] Folch, Jos[eacute] I. Gonz[aacute]lez, Jose M. Ordovas
Journal: Metabolism (2001)
Side Effects May Include
Authors: Adam Possner
Journal: JAMA (2010)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Physician's Stake in Animal Research
Authors: Rollin Odell
Journal: JAMA (1986)

<h3>To the Editor.—</h3> Dr Wyngaarden's recent editorial<sup>1</sup>regarding the use of animals in biomedical research is narrowly focused, does not take into account the broad-based nature of support in the United States of radical animal rights groups, and smacks of an arrogance unbecoming to the medical profession. The recommendations made for countering animal rights advocates will only galvanize them into greater activity. As a speaker for the American Cancer Society in California to numerous lay groups, I have been impressed by the skepticism of the general public toward medical "advances." They do not share the dream (or is it fantasy?) that increased knowledge of the human body will solve the problems of suffering and premature death. Indeed, there is a growing awareness that illness can only be understood within the broader context of the whole culture. Organ transplants, bypass surgery, and mood-controlling drugs are seen by many as mixed
AUTOLOGOUS BONE-MARROW MONONUCLEAR CELLS AMELIORATE SYMPTOMS BY ENHANCING PERFUSION INDICES IN PATIENTS WITH END-STAGE PERIPHERAL ARTERIAL DISEASE
Authors: Nasser M. Malyar, Khalil Malyar, Jawed Arjumand, Stefan Radtke, Bernd Giebel, Peter A. Horn, Knut Kroeger, Franz-Eduard Brock
Journal: Journal of the American College of Cardiology (2011)
Evaluating the Effects of Ambient Air Pollution on Life Expectancy
Authors: Daniel Krewski
Journal: New England Journal of Medicine (2009)

Air pollution is an important determinant of population health.In this issue of the Journal, Pope et al. 1 provide data that once again reinforce this fundamental concept.In an analysis that correlates reductions in fine particulate matter (i.e., particles less than 2.5 μm in aerodynamic diameter, or PM 2.5 ) in the air with life expectancies , the investigators found that a decrease in the concentration of PM 2.5 of 10 μg per cubic meter is associated with an increase in life expectancy of 0.77 year.Their analysis is based on correlating reductions in particulate air pollution over the past several decades with increases in life expectancy in 217 counties in 51 metropolitan areas in the United States.Although ecologic in nature (i.e., reflecting associations between air pollution and life expectancy at the county rather than the individual level), these results appear to be robust with respect to adjustment for changes in socioeconomic, demographic, and smoking patterns occurring over the same period.The finding is comparable with previous predictions of reductions in life expectancy of 1.11 years in the Netherlands, 2 1.37 years in Finland, 3 and 0.80 year in Canada 4 resulting from increases in ambient PM 2.5 concentrations of 10 μg per cubic meter.However, the strength of the study by Pope et al. resides in its ability to demonstrate an increase in life expectancy resulting from actual reductions in particulate air pollution.This finding provides direct confirmation of the population health benefits of mitigating air pollution and greatly strengthens the foundation of the argument for air-quality management. 5 This work could be extended to take into account quality of life.For example, Coyle et al.
Scintigraphic evaluation in rabbits of nasal drug delivery systems based on carbopol 971p® and carboxymethylcellulose
Authors: Michael Ikechukwu Ugwoke, Remigius Uchenna Agu, Hubert Vanbilloen, Jan Baetens, Patrick Augustijns, Norbert Verbeke, Luc Mortelmans, Alfons Verbruggen, Renaat Kinget, Guy Bormans
Journal: Journal of Controlled Release (2000)
Non-Renal Effects and the Risk Assessment of Environmental Cadmium Exposure
Authors: Agneta Åkesson, Lars Barregard, Ingvar A. Bergdahl, Gunnar F. Nordberg, Monica Nordberg, Staffan Skerfving
Journal: Environmental Health Perspectives (2014)

Background: Exposure to cadmium (Cd) has long been recognized as a health hazard, both in industry and in general populations with high exposure. Under the currently prevailing health risk assessment, the relationship between urinary Cd (U-Cd) concentrations and tubular proteinuria is used. However, doubts have recently been raised regarding the justification of basing the risk assessment on this relationship at very low exposure.Objectives: Our objective was to review available information on health effects of Cd exposure with respect to human health risk assessment.Discussion: The associations between U-Cd and urinary proteins at very low exposure may not be due to Cd toxicity, and the clinical significance of slight proteinuria may also be limited. More importantly, other effects have been reported at very low Cd exposure. There is reason to challenge the basis of the existing health risk assessment for Cd. Our review of the literature found that exposure to low concentrations of Cd is associated with effects on bone, including increased risk of osteoporosis and fractures, and that this observation has implications for the health risk assessment of Cd. Other effects associated with Cd should also be considered, in particular cancer, although the information is still too limited for appropriate use in quantitative risk assessment.Conclusion: Non-renal effects should be considered critical effects in the health risk assessment of Cd.Citation: Åkesson A, Barregard L, Bergdahl IA, Nordberg GF, Nordberg M, Skerfving S. 2014. Non-renal effects and the risk assessment of environmental cadmium exposure. Environ Health Perspect 122:431–438; http://dx.doi.org/10.1289/ehp.1307110
Abstract 4848: A synthetic-lethal screen identifies novel Mcl1 regulators in neuroblastoma
Authors: Theodore Laetsch, Xueyuan Liu, Michael Sliozberg, Michael Vido, Annette Vu, Kelly Goldsmith, Michael D. Hogarty
Journal: Cancer Research (2012)

Abstract Neuroblastoma (NB) is a lethal pediatric tumor. Despite multimodal therapy survival remains poor due to emergent chemoresistance governed by Bcl2-homology (BH) proteins. Agents that antagonize BH proteins, such as ABT-737, are in clinical development. ABT-737 does not antagonize Mcl1, a Bcl2-homologue correlated with ABT-737 resistance in many tumors. We defined the survival bias present in NBs using functional mitochondrial profiling in response to diverse BH3 death-domain peptides. Those with a functional Bcl2-dependence were exquisitely sensitive to ABT-737 in vitro and in vivo. Those with an Mcl1-dependence were relatively ABT-737 resistant (3-5 uM IC50s), yet Mcl1 knock-down restored ABT-737 activity in this subset (nM IC50s). We therefore undertook a synthetic-lethal screen for Mcl1 regulators using siRNA against deubiquitinating enzymes (DUBs), as Mcl1 is highly regulated with a short half-life due to ubiquitin-mediated degradation and this genomic space has many plausible druggable targets. We treated Mcl1-dependent NB cell lines (IMR5 and NLF) with siRNA targeting DUBs and ABT-737 at a sublethal concentration (200 nM). This screen identified 5 targets (of 98) demonstrating synthetic lethality (Z&amp;lt;-1.5) that was selective for Mcl1-dependent NBs. We validated these by measuring ABT-737 IC50s in vitro with and without siRNA knockdown and confirmed a &amp;gt;10-fold decrease in IC50 for 4 of 5 targets. Three further demonstrated a &amp;gt;10-fold decrease in ABT-737 IC50 with multiple independent siRNA supporting these as on-target effects (4/4 for PSMD14, 3/4 for PRPF8, and 2/4 for UBL5). We show that we can rescue the PSMD14 and UBL5 knock-down phenotypes by expression of an siRNA-resistant expression plasmid. While knock-down of all three targets decreases Mcl1 function, only knock-down of UBL5 (downregulates) and PSMD14 (upregulates) alter Mcl1 protein expression. We hypothesize that knock-down of PSMD14 and PRPF8 decrease Mcl1 activity through inhibitory post-translational modifications despite paradoxical or absent effects on Mcl1 protein expression, while UBL5 stabilizes Mcl1 as a ubiquitin-like PTM. Thus, we have demonstrated the robustness of a novel synthetic lethal screen to identify modulators of Mcl1 activity in vitro and identified three novel therapeutic targets regulating Mcl1 activity in NB. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4848. doi:1538-7445.AM2012-4848
Tracy's The Doctor as a Witness
Authors: George E. Hall
Journal: JAMA (1965)

As Ogden Nash has written: "The noblest lord is ushered in by a registered physician, and the humblest lout is ushered out by a certified mortician, and in between they find their foyers crowded with summonses from lawyers." The physician who is worried about these "in-betweens," (and what physician is not), will find great help and solace in between the covers of this little book. The original edition was written by Professor John Evarts Tracy, now deceased, but formerly on the faculty of the University of Michigan Law School. It was then, and in its second edition is still, one of the best primers on the medical expert witness. Professor Curran carries the reader from the institution of a lawsuit and the obligations of the physician to testify in proper cases in which he possesses a knowledge not possessed by others, through the steps he should take to prepare himself
A Rare Cause of Dysphagia
Authors: Martin P. Dumler
Journal: JAMA (1966)

THE ETIOLOGY of dysphagia is varied and generally categorized as to the patient's age. During neonatal life and childhood, congenital malformations, corrosive esophagitis, foreign bodies, and achalasia are the more common causes. In the adult and elderly, neoplasms, hiatal hernias, diverticula, esophagitis, and cardiospasm are the major factors in dysphagia, with carcinoma being most prominent. This case report is thought to be quite unique since the main cause for the dysphagia was a malformation of the left pulmonary artery. A malformation such as this is apparently rare. No previous reports in an adult were found in the literature although three cases have been reported in infants. Welsh and Munro,<sup>1</sup>in 1954; Potts et al,<sup>2</sup>in 1954; and Morse and Gladding,<sup>3</sup>in 1955, presented three separate case reports of infants with symptoms of obstruction of the right main bronchus. Even though this vascular malformation is extremely uncommon, it
Verruca Vulgaris Not Cured by Immune Globulin
Authors: Hugh A. Johnson
Journal: JAMA (1966)

<h3>To the Editor:—</h3> Conflicting opinions of the value of immune globulin in the prevention, amelioration, and cure of certain viral diseases are reported. The virus that causes verruca vulgaris, common as it is, must produce specific antibodies; hence the spontaneous regression. He who treats intractable warts is willing to grasp at almost any straw to relieve the poor patients who have widespread warts around the nail beds and on the soles of the feet. Seven such patients have been treated with immune globulin. In only one did the warts disappear promptly. In a disease that has spontaneous remission one cure in seven treated cases could not be statistically significant.
STIMULATION OF LUTEINISING HORMONE (L.H.) RELEASE AFTER ORAL ADMINISTRATION OF AN ANALOGUE OF L.H. RELEASING HORMONE
Authors: David Gonzalez-Barcena, M Clinton Miller, DavidH Coy, AbbaJ Kastin, DonS Schalch, AndrewV Schally, Antonio Escalante-Herrera
Journal: The Lancet (1975)
297 Improved adherence to pegylated interferon alpha 2B + ribavirin in academic centers vs. community-based centers: results from a prospective, randomized, controlled, multicenter trial
Authors: S FLAMM, J GOLDMAN, G NELLIGAN, J CAHAN, D CHUA, B SHAPIRO, R YAPP, E JURKOVIC, T SEPE, R BROWN
Journal: Hepatology (2003)
Electrocardiographic manifestations of concealed junctional ectopic impulses.
Authors: C Fisch, D P Zipes, P L McHenry
Journal: Circulation (1976)

Thirteen episodes of concealed junctional ectopic impulses (JEI) in ten patients are described. In nine patients the JEI manifested as isolated automatic impulses and in one as a parasystolic junctional tachycardia. In addition to the previously described unexpected prolongation of the P-R, Type I and Type II A-V block, the following phenomena were recorded: 1) marked, greater than 400 msec, and persistent prolongation of the P-R interval, 2) striking changes in the duration of the P-R with an occasional sequence of R-P and P-r intervals simulating "supernormal" A-V conduction, 3) unexpected variation of the junctional escape interval explained by junctional parasystole with entrance block, 4) postponed compensatory pause, 5) concealed junctional discharge with reciprocation.
Predicting child abuse.
Authors: R R Gordon
Journal: BMJ (1977)

Respiratory side effects of beta-blockers SIR,-I would like to comment on one aspect of the hazards of beta-blockers (leading article, 26 February, p 529)-namely, their use in patients with airways obstruction.It is well known that blockade of beta2 receptors may lead to bronchoconstriction in asthmatics.'This risk is said to be less with the so-called selective beta-blockers, which block predominantely the beta, receptors.My
Macrophage Apoptosis Exerts Divergent Effects on Atherogenesis as a Function of Lesion Stage
Authors: Emmanuel L. Gautier, Thierry Huby, Joseph L. Witztum, Betty Ouzilleau, Elizabeth R. Miller, Flora Saint-Charles, Pierre Aucouturier, M. John Chapman, Philippe Lesnik
Journal: Circulation (2009)

Background— Because apoptotic cell clearance appears to be defective in advanced compared with early atherosclerotic plaques, macrophage apoptosis may differentially affect plaque progression as a function of lesion stage. Methods and Results— We first evaluated the impact of targeted protection of macrophages against apoptosis at both early and advanced stages of atherosclerosis. Increased resistance of macrophages to apoptosis in early atherosclerotic lesions was associated with increased plaque burden; in contrast, it afforded protection against progression to advanced lesions. Conversely, sustained induction of apoptosis in lesional macrophages of advanced lesions resulted in a significant increase in lesion size. Such enhanced lesion size occurred as a result not only of apoptotic cell accumulation but also of elevated chemokine expression and subsequent intimal recruitment of circulating monocytes. Conclusions— Considered together, our data suggest that macrophage apoptosis is atheroprotective in fatty streak lesions, but in contrast, defective clearance of apoptotic debris in advanced lesions favors arterial wall inflammation and enhanced recruitment of monocytes, leading to enhanced atherogenesis.
Writing a thesis on a word processor
Authors: R Villar
Journal: BMJ (1984)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Writing a thesis on a word processor Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Struma Ovarii—Ascitic, Hyperthyroid, and Asymptomatic Syndromes
Authors: Roger D. Kempers, Malcolm B. Dockerty, David L. Hoffman, Lloyd G. Bartholomew
Journal: Annals of Internal Medicine (1970)

A clinicopathologic study was made of 25 cases of struma ovarii. Significant ascites was present in nine cases, only four of which were malignant. Pleural effusion was present in two cases of benign struma and in one case of malignant struma not associated with pleural metastasis. Eight patients had hyperthyroidism; five of these eight also had adenomatous or colloid cervical goiters. Eleven patients had neither ascites nor hyperthyroidism and were classified as asymptomatic. These patients were either completely asymptomatic or complained of pelvic pressure related to a pelvic mass. One fifth of the tumors were malignant. They were of low grade, often treatable with 131l, and carried a favorable prognosis. In all but five cases it was evident that the neoplasm was grossly a teratoma. Microscopically, all showed features of multiadenomatous thyroid.
971-55 Can Regional Myocardial Tissue Blood Flow be Measured in Terms of ml/min/g Using Contrast Echocardiography?
Authors: Victor Mor-Avi, Sanjeev G, None Shroff, Kimberly A. Robinson, Philippe R. Vignon, Arthur F. Ng, Claudia Korcarz, Solange Akselrod, Roberto M. Lang
Journal: Journal of the American College of Cardiology (1995)
FUNCTIONAL RATIOS OF NORMAL SALIVARY GLANDS USING DUAL DETECTOR GAMMA CAMERA AND GEOMETRIC MEAN
Authors: E. S. Delpassand, F. Zare, W. Broussard, M. Mathai, R. Jacob, D. A. Podoloff
Journal: Clinical Nuclear Medicine (1997)

Delpassand, E. S.; Zare, F.; Broussard, W.; Mathai, M.; Jacob, R.; Podoloff, D. A. Author Information
Iepatic vitamin D 25-hydroxylase: Inhibition by bile duct ligation or bile salts
Authors: Erry J. G. Bolt, Michael D. Sitrin, Murray J. Favus, Irwin H. Rosenberg
Journal: Hepatology (1981)

Bone disease and low serum levels of 25-hydroxyvitamin D are prevalent in cholestatic syndromes such as primary biliary cirrhosis and biliary atresia. Defective hydroxylation, along with malabsorption of vitamin D, could be a factor in 25-hydroxyvitamin D depletion. To assess hepatic hydroxylation during experimental cholestasis, we studied vitamin D 25-hydroxylase activity in liver homogenates of rats after 7, 14, and 21 days of bile duct ligation. We have also studied the effects of bile acids on this enzyme in vitro. Hepatic 25-hydroxylation was depressed after 7 days ligation in only 1 of 4 animals, but by 14 days, all animals showed a marked reduction with a mean decrease of 64% in specific activity. Total liver enzyme activity was reduced by 43% at 14 days. In the ligated animals, liver histology showed progressive bile stasis, focal necrosis, bile ductular proliferation, periductular and periportal inflammation, and fibrosis. Addition of bile acids to the in vitro assay in concentrations approximating those found in cholestasis produced marked inhibition of vitamin D 25-hydroxylase activity.
Dr Takemi and the Atomic Bomb
Authors: Daniel T. Cloud
Journal: JAMA (1995)

WHEN the United States dropped the atomic bomb on Hiroshima 50 years ago, a young Japanese physician named Tarô Takemi, within hours, correctly analyzed the nature of the holocaust, then risked his life in a brazen effort to win time for the Japanese military leaders to come to their senses and surrender. Nearly four decades after the bombing of Hiroshima, Takemi treated me to a personal account of his remarkable venture. It was a riveting tale of courage and legerdemain, and hearing it first hand from Takemi was a moving experience. Equally moving was the haunting Takemi memoir, wherein he reported the story in greater detail, though characteristically understated, published in<i>JAMA</i>only months before his death.<sup>1</sup> When I first met Takemi, in 1979, I was somewhat taken aback. "This guy is right out of central casting," I thought. He was short and bandy-legged with a balding bullethead, furrowed